Milla E.L. Kuusisto

<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen et al. · Haematologica · 2022 · 46 citations · Full text

Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma

Siria Lemma, Milla E.L. Kuusisto, Kirsi‐Maria Haapasaari et al. · Carcinogenesis · 2017 · 26 citations · Full text

Immunology, Pathology, Potential Biomarkers +17

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta et al. · Blood · 2024 · 24 citations

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP

Esa Kari, Hanna‐Riikka Teppo, Kirsi‐Maria Haapasaari et al. · Journal of Clinical Pathology · 2019 · 16 citations · Full text

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era

Roosa Prusila, Marc Sorigué, J. Jauhiainen et al. · British Journal of Haematology · 2019 · 15 citations · Full text